Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting
Keros Therapeutics, Inc. - common stock (KROS)
Company Research
Source: GlobeNewswire
LEXINGTON, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it presented additional clinical data from its Phase 1 clinical trial of KER-065 in healthy male volunteers at the American Society of Bone and Mineral Research 2025 Annual Meeting on Saturday, September 6, 2025. “We are pleased to present additional data that highlights the broad therapeutic potential of KER-065, including its robust bone anabolic activity,” said Jasbir S. Seehra, President and Chief Executive Officer. “These data continue to demonstrate the potential of KER-065 in Duchenne muscular dystrophy, where bone loss occurs as a result of the progressive muscle weakness and chronic use of
Show less
Read more
Impact Snapshot
Event Time:
KROS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KROS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KROS alerts
High impacting Keros Therapeutics, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
KROS
News
- Keros Therapeutics (NASDAQ:KROS) had its price target raised by analysts at Bank of America Corporation from $18.00 to $19.00. They now have a "neutral" rating on the stock.MarketBeat
- How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% [Yahoo! Finance]Yahoo! Finance
- Keros Therapeutics Announces Final Results of Tender Offer [Yahoo! Finance]Yahoo! Finance
- Keros Therapeutics Announces Final Results of Tender OfferGlobeNewswire
- Keros Therapeutics Announces Preliminary Results of Tender OfferGlobeNewswire
KROS
Earnings
- 11/5/25 - Beat
KROS
Sec Filings
- 11/20/25 - Form SC
- 11/19/25 - Form SC
- 11/18/25 - Form SCHEDULE
- KROS's page on the SEC website